TriSalus Life Sciences (NASDAQ:TLSIW) Shares Up 6.9% – Should You Buy?

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) shares rose 6.9% during mid-day trading on Tuesday . The company traded as high as $1.29 and last traded at $1.09. Approximately 1,671 shares were traded during mid-day trading, an increase of 40% from the average daily volume of 1,193 shares. The stock had previously closed at $1.02.

TriSalus Life Sciences Stock Down 6.4 %

The company’s 50 day simple moving average is $1.15 and its 200 day simple moving average is $1.26.

Hedge Funds Weigh In On TriSalus Life Sciences

An institutional investor recently bought a new position in TriSalus Life Sciences stock. Bluefin Capital Management LLC bought a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 115,989 shares of the company’s stock, valued at approximately $189,000.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.